Codexis (NASDAQ:CDXS) Issues Earnings Results

Key Points

• Codexis beat quarterly expectations: The company reported an adjusted loss of $0.13 per share versus the $0.14 consensus loss, while revenue of $14.91 million exceeded estimates of $13.82 million. Product gross margin improved to 73%.
• Cash position and growth initiatives strengthened: A financing raised approximately $25 million, extending the expected cash runway through 2028. Codexis is advancing ECO Synthesis commercialization and plans to begin construction of a roughly $25 million GMP RNA manufacturing facility after permitting.
• Risks and investor caution remain: The company continues to report losses, and reaching its $72 million–$76 million 2026 revenue target requires a substantial second-half increase. Shares fell 1.3% to $1.48, while analysts’ average rating remained “Hold” with a $5.00 price target.

Codexis (NASDAQ:CDXS - Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01, FiscalAI reports. Codexis had a negative net margin of 40.97% and a negative return on equity of 68.09%. The business had revenue of $14.91 million for the quarter, compared to analyst estimates of $13.82 million.

Here are the key takeaways from Codexis' conference call:

• Financial flexibility improved: Second-quarter revenue was $14.9 million, while product gross margin rose to 73%; management now expects full-year 2026 gross margin in the high 60s. A recent financing generated approximately $25 million in net proceeds, extending the projected cash runway through 2028.
• ECO Synthesis gained commercial traction: New data on precise phosphorothioate stereochemistry and starterless synthesis generated strong customer interest, with several engagements advancing and one of three CDMO partners entering negotiations for a long-term commercial contract.
• RNA manufacturing scale-up remains on track: Codexis plans to begin construction of its approximately $25 million GMP facility after permitting, advance ECO Synthesis production from hundreds of grams toward 500 grams by year-end and eventually kilogram scale, and support customer IND filings and clinical trials.
• Small-molecule biocatalysis is returning to growth: The business remains profitable and benefits from higher-margin products, four partner drug approvals in 2026, a label expansion, and 15 programs in Phase II or III; management sees potential for high-single-digit long-term growth, although sales can remain lumpy.
• Execution and commercialization risks remain: Revenue declined modestly year over year to $14.9 million, the company continues to post quarterly losses, and its $72 million–$76 million 2026 revenue target requires a significant second-half ramp. ECO Synthesis also still faces technical scale-up, customer adoption and contract-conversion risks.

Codexis Trading Down 1.3%

Shares of NASDAQ CDXS traded down $0.02 during mid-day trading on Tuesday, hitting $1.48. 867,577 shares of the company traded hands, compared to its average volume of 1,593,090. The business has a 50 day moving average of $2.18 and a two-hundred day moving average of $1.98. The company has a quick ratio of 5.23, a current ratio of 5.36 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $134.53 million, a price-to-earnings ratio of -4.00 and a beta of 2.54. Codexis has a 1 year low of $0.96 and a 1 year high of $3.87.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wall Street Zen cut Codexis from a "buy" rating to a "hold" rating in a research note on Sunday, May 3rd. Weiss Ratings upgraded Codexis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, July 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Codexis in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $5.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. State of Wyoming acquired a new stake in shares of Codexis during the second quarter valued at approximately $25,000. Victory Capital Management Inc. acquired a new position in Codexis in the 3rd quarter worth approximately $25,000. CIBC Bancorp USA Inc. purchased a new position in Codexis during the 3rd quarter worth approximately $26,000. BNP Paribas Financial Markets grew its position in Codexis by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,608 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 8,038 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in Codexis during the 4th quarter valued at $45,000. 78.54% of the stock is owned by hedge funds and other institutional investors.

Codexis Company Profile

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source